| Filed On | Filing |
|---|---|
| 14 May 2020 |
8-K: Material Modification to Rights of Security Holders
On May 14, 2020 (the “Settlement Date”), AbbVie Inc. (“AbbVie”) completed its previously announced (i) offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) any and all outstanding notes of certain serie... |
| 08 May 2020 |
8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +5 more
The Company is a public limited company deemed to be a PLC to which Part 17 of the Companies Act 2014 applies. |
| 06 May 2020 |
8-K: Other Events
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION |
| 21 Apr 2020 |
8-K: Temporary Suspension of Trading Under Employee Benefit Plans; Other Events
A. Robert D. Bailey, Executive Vice President & Chief Legal Officer |
| 18 Mar 2020 |
8-K: Other Events
NORTH CHICAGO, Ill. and DUBLIN, March 17, 2020/PRNewswire/ – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that they have en... |
| 03 Mar 2020 |
8-K: Other Events
NORTH CHICAGO, Ill. and DUBLIN, March 3, 2020 /PRNewswire/ – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the European... |
| 10 Feb 2020 |
8-K: Results of Operations and Financial Condition
- Full-Year 2019 GAAP Net Revenues of $16.1 Billion; Q4 2019 GAAP Net Revenues of $4.4 Billion - |
| 27 Jan 2020 |
8-K: Other Events
Agreements Contingent on FTC and European Commission Approval and Completion of AbbVie’s Pending Acquisition of Allergan |
| 05 Nov 2019 |
8-K: Results of Operations and Financial Condition
Non-GAAP Net revenues grew 3.6% to $4,026M versus prior year. |
| 05 Nov 2019 |
8-K: Results of Operations and Financial Condition
- Q3 2019 GAAP Loss Per Share of $2.40; Non-GAAP Performance Net Income Per Share of $4.25 - |
| 15 Oct 2019 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION |
| 27 Sep 2019 |
8-K: Other Events
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION |
| 16 Sep 2019 |
8-K: Regulation FD Disclosure
We report on the profit forecast comprising the statement by Allergan plc (“Allergan”) and its subsidiaries (together the “Allergan Group”) in respect of non-GAAP Net Income per share for the year ending 31 December 2019 (the “Profit For... |
| 11 Sep 2019 |
8-K: Other Events
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION |
| 06 Aug 2019 |
8-K: Results of Operations and Financial Condition
GAAP Net revenues grew 0.6% and non-GAAP Net revenues grew 1.2% to $4,090M. |
| 06 Aug 2019 |
8-K: Results of Operations and Financial Condition
– Q2 2019 GAAP Loss Per Share of $5.37; Non-GAAP Performance Net Income Per Share of $4.38 – |
| 25 Jun 2019 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION |
| 07 May 2019 |
8-K: Results of Operations and Financial Condition
-- Q1 2019 GAAP Loss Per Share of $7.25; Non-GAAP Performance Net Income Per Share of $3.79 -- |
| 01 May 2019 |
8-K: Submission of Matters to a Vote of Security Holders
On May 1, 2019, Allergan plc (the “Company” or “Allergan”) held its 2019 Annual General Meeting of Shareholders (the “AGM”) in Dublin, Ireland. There were 332,730,264 ordinary shares of Allergan outstanding as of March 5, 2019, the recor... |
| 22 Mar 2019 |
8-K: Other Events
On March 22, 2019, Allergan plc (“Allergan”) filed its 2019 definitive proxy materials with the Securities and Exchange Commission in connection with the Company’s Annual General Meeting of Shareholders to be held on May 1, 2019, which i... |
Loading...